Table 2

Prevalence of Individual FCI Comorbidities by Data Collection Method (n = 59)
FCI Comorbidity, n (%) Gold Standard Chart Abstraction Prospective: Admission Records p-value* Retrospective: Discharge Summaries p-value**
Arthritis (rheumatoid and osteoarthritis) 5 (8) 1 (3) 0.05 3 (5) 0.41
Osteoporosis 0 (0) 0 (0) n/a 1 (2) 0.32
Asthma 7 (12) 2 (3) 0.03 6 (10) 0.32
COPD, emphysema, or ARDS 7 (12) 0 (0) <0.01 5 (8) 0.32
Angina 1 (2) 0 (0) 0.32 0 (0) 0.32
Congestive heart failure (or heart disease) 10 (17) 5 (8) 0.05 8 (14) 0.16
Myocardial infarction 2 (3) 2 (3) 1.00 1 (2) 0.32
Neurological disease (e.g., MS or Parkinson’s) 6 (10) 0 (0) 0.01 8 (14) 0.16
Stroke or TIA 4 (7) 5 (8) 0.32 4 (7) 1.00
Peripheral vascular disease 4 (7) 1 (3) 0.08 3 (5) 0.32
Diabetes type I or II 10 (17) 9 (15) 0.56 10 (17) 1.00
Upper GI disease (e.g., ulcer, hernia, reflux) 23 (39) 4 (7) <0.01 24 (41) 0.71
Depression 15 (25) 3 (5) <0.01 11 (19) 0.16
Anxiety or panic disorders 6 (10) 0 (0) 0.01 6 (10) 1.00
Visual impairment (e.g., cataracts, glaucoma) 0 (0) 0 (0) 1.00 1 (2) 0.32
Hearing impairment (e.g., hard of hearing with aids) 0 (0) 0 (0) n/a 0 (0) n/a
Degenerative disc disease (e.g., spinal stenosis) 3 (5) 0 (0) 0.08 2 (3) 0.32
FCI Score, median (IQR)*** 2 (1–3) 1 (0–1) <0.01 1 (1–2) <0.01

Abbreviations: ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; MS, multiple sclerosis; TIA, transient ischemic attack.

* p-value comparing prospective data collection to chart abstraction, using McNemar’s test.

** p-value comparing retrospective data collection to chart abstraction, using McNemar’s test.

*** For the FCI score, comparison made using Wilcoxon signed-rank test.

Fan et al.

Fan et al. BMC Anesthesiology 2012 12:21   doi:10.1186/1471-2253-12-21

Open Data